Introduction
The p53 tumor suppessor plays an important role during tumorigenesis. Wild type (wt) p53 is involved in cell cycle control, apoptosis and stabilization of the cellular genome, functions which can go awry during tumorigenesis (reviewed by Levine et al., 1991; Donehower and Bradley, 1993) . In untransformed cells, p53 levels are usually low but after exposure to DNA damaging agents the levels rise, perhaps because of metabolic stabilization (Maltzman and Czyzyk, 1984; Fritsche et al., 1993) . High levels of p53 may act to protect the cellular genome, in part by arresting cell growth (Kastan et al., 1991) , although functional removal of wt p53 may also cause cell cycle arrest (Lane, 1992; Mercer et al., 1984) . Many human tumors contain mutant p53 and it is likely that these mutants are no longer able to control cell growth (Hollstein et al., 1991) . Mutant p53 can act as a dominant oncogene when introduced into cells and can cooperate with the other oncogenes to produce cell transformation (Michalovitz et al., 1986; Levine et al., 1991; Donehower and Bradley, 1993) .
p53 was ®rst discovered because it coprecipitated with large T-Ag in SV40 T-Ag transformed murine cells (Lane and Crawford, 1979; Linzer and Levine, 1979) . In these transformants the amount of p53 was greatly elevated but was apparently complexed with TAg. Complex formation stabilized p53, but also sequestered it, perhaps preventing it from controlling cell growth (Moore et al., 1992 ; reviewed by Levine et al., 1991) . While the amount of p53 was greatly elevated in T-Ag transformed cells, immunoprecipitation analysis of metabolically labelled proteins indicated that it was present in amounts nearly equal to T-Ag (Crawford, 1983) . However, unlike T-Ag transformed mouse cells, the transformed human cell line SV80 contained unbound p53 and unbound T-Ag (Lane and Crawford, 1980) . Analysis of mutant T-Ags has shown that the ability to cause immortalization correlates with the ability to bind p53 (Lin and Simmons, 1991b; Zhu et al., 1991; Kierstead and Tevethia, 1993) . As with TAg, other viral oncoproteins contain domains which bind p53 resulting in its functional inactivation (Whyte et al., 1989; Werness et al., 1990) . However, inactivation may occur by dierent mechanisms (Werness et al., 1990; Hansen et al., 1995) . The sequestration and inactivation of p53 by viral oncoproteins is perhaps an important step in viral oncogenesis (Levine et al., 1991; .
However, alternate explanations have been proposed for the activity of p53 in T-Ag transformants Simmons, 1990, 1991b; , including the possibility that the T-Ag/p53 complex itself is a heteromeric oncoprotein (Lin and Simmons, 1991b) . In the present report, we investigated T-Ag/p53 complexes in human cells transformed by wt and several variant SV40 T-Ags, including the temperature sensitive mutant tsA58. The variant T-Ags transformed human cells at a frequency at least equal to that of wtSV40 T-Ag. Using Western analysis of immunopre- p403/ E-SV40 p407/E-SV40 c d Figure 1 Immunoprecipitation analysis of T-Ag and p53 in metabolically labelled cells. Rapidly growing cells were labelled with 35 Stranslabel; (I & N Pharmaceuticals) at a concentration of 60 mCi/ml for 4 h. Proteins were extracted and immunoprecipitated for T-Ag or p53 as described in Materials and methods. Protein concentrations were measured by a modi®ed Lowry procedure (BioRad Laboratories) and radioactivity was measured by liquid scintillation. The same amount of radioactivity was then loaded into each lane of a polyacrylamide gel and subjected to electrophoresis as described (O'Neill et al., 1995) . For most cell clones, both a T-Ag lane and a p53 lane are shown, and the position of each protein is noted. In several of the p53 lanes, a third band at a position corresponding to 150 Kd is observed (a, lanes 2, 4 and 6). This represents a protein which cross-reacts with p53 speci®c antibodies and is thought to disappear in transformants which have become immortal (van den Heuvel et al., 1992) . Some of our immortal transformants appear to still contain this band (a, lane 2). Also a band at the same position is sometimes observed in T-Ag immunoprecipitates (b, lane 8; c, lanes 2 and 4). (a): Lanes 1 ± 8 are extracts from cells transformed by wt T-Ag and propagated at 378C. Lane 9 is from untransformed cells. Lanes 1, 2, 7 and 8 are from immortal cell lines. (b) and (c) are mostly from tsA58 T-Ag transformed cells propagated at 378C (b) or 408 (c). In the 408 experiments, the cells were usually propagated for 2 or 3 days at the high temperatures. Lane 1 of both panels shows the p53 immunoprecipitate from a wt T-Ag transformant. For tsA58 T-Ag transformants, note that while a p53 immunoprecipitate coprecipitates a small amount of T-Ag in cells grown at 378C (b, lanes 3, 5, 7, 9 and 11) almost no T-Ag is coprecipitated from cells grown at 408C (c, lanes 3, 5, 7 and 9). In addition, from tsA58 transformants propagated at 378C a p53 immunoprecipitate coprecipitates more T-Ag than does a T-Ag immunoprecipitation coprecipitate p53. Experiments were also done at 338C with tsA58-transformants but these are not shown because the results were very similar to those at 378C. (d) shows immunoprecipitates from variant T-Ag transformants grown at 378C. pSRSMT-NsiI is a SV40/JCV chimeric T-Ag transformant, and p407/E-SV40 and p403/E-SV40 are SV40/BKV-1 chimeric T-Ag transformants (O'Neill, 1995) . See also lane 12, (b). Lanes 7 ± 9 of (a) and 1 and 2 of (d) were run on gels separate from the gel which contains the other lanes in that panel. The transformant labelled pSRSMT-NsiI clone 2 in (b) and (d) is derived from HFB cells while all the others are HFF-495 cells cipitates, we found that in most cell lines, even those transformed by variant T-Ags, nearly all of the T-Ag eventually became bound to p53, but most of the p53 remained unbound to T-Ag. p53 was usually present in amounts two to fourfold greater than T-Ag and 200-fold greater than the total p53 levels in untransformed cells. The unbound p53 was also present in large amounts in transformants which became immortal. Finally, in several of the variant T-Ag transformants, T-Ag formed complexes with p53 slowly.
Results

Transformation eciency of various T-Ags for human cells
We compared focus formation by wtSV40 T-Ag and the variant T-Ags. Wt T-Ag and tsA58 T-Ag induced dense foci in human ®broblasts (HFF495) at a frequency of 18 ± 22 foci per microgram of viral DNA and focus formation by all of the variants was similar to that of wt T-Ag, except pSRSMT-NsiI which produced dense foci at a rate of 30 ± 35 foci per microgram of viral DNA (Table 1, and O'Neill et al., 1995) . While pSRSMT-NsiI, p403/E-SV40 and p407/E-SV40 produced transformants which became immortal at a high rate, wt T-Ag transformants and tsA58 transformants immortalized at a frequency of 10 ± 20% (Table 1 and O'Neill et al., 1995) . This suggests that TAg directly in¯uences the immortalization process. All but the tsA58 T-Ag induced transformants could be propagated at 338C, 378C and 408C; those produced by tsA58 T-Ag entered crisis, became growth arrested, and then died when propagated at 408C (Table 1) .
Immunoprecipitation analysis of metabolically labelled SV40 T-Ag and p53
Several laboratories have shown that when either T-Ag or p53 is immunoprecipitated from metabolically labeled transformed cells, the second protein is coprecipitated (reviewed by Crawford et al., 1983; Levine et al., 1991) . This indicated that T-Ag and p53 formed a complex in transformed cells. It was shown that transformed rodent cells contained in the complex, nearly equal amounts of both proteins (Crawford, 1983) . When we performed these experiments with human cells transformed by wt and variant T-Ags, we noted that unlike most of the wt T-Ag transformants, most of the variant T-Ag transformants appeared to contain less p53 coprecipitating with T-Ag. This is demonstrated in Figure 1 which shows T-Ag immunoprecipations from several transformants. In most of the wt transformants but not all, there are relatively large amounts of p53 coprecipitating with T-Ag ( Figure 1a lanes 1, 3, 5 and 7). In contrast, when cells transformed by tsA58 T-Ag were analysed, little p53 appears to coprecipitate with T-Ag (Figure 1b lanes 2, 4, 6, 8 and 10, c lanes 2, 4, 6 and 8). This was observed at both permissive (338C or 378C) and non-permissive temperatures (408C), and at 408C p53 was virtually undetectable in T-Ag immunoprecipitates ( Figure 1c ). Also, when p53 was immunoprecipitated from tsA58-transformants propagated at 378C or 408C, there was little T-Ag coprecipitated (Figure 1b and c). Metabolically labelled T-Ag and p53 also failed to completely coprecipitate in cells transformed by other variant T-Ags, including the SV40/JCV and SV40/BKV-1 chimeric T-Ags (pSRMSMT/NsiI, p403/E-SV40 and p407/E-SV40) ( Figure 1b lane 12, d ). This observation with pSRSMT-NsiI transformants was made previously where it was suggested (O'Neill et al., 1995) that the reduced complex formation may re¯ect the reduced ability of JCV T-Ag to bind p53 (Haggerty et al., 1989) . Analysis of metabolically labelled proteins recovered from tsA58 T-Ag transformants propagated at 378C showed that T-Ag appeared to have coprecipitated with p53 in greater amounts than did p53 coprecipitate with T-Ag (Figure 1b , all clones). This suggested that some of the labelled T-Ag had coprecipitated with immunoprecipitated unlabelled p53. Below, we have examined the complexes from both wt and tsA58 transformants at steady state conditions using Western blotting. (Carroll and Gurney, 1982; Kraiss et al., 1988; Kierstead and Tevethia, 1993) . In tsA58-transformed cells, while little labelled p53 coprecipitated with labelled T-Ag, there may be relatively large amounts of coprecipitated p53 which is unlabelled because it was synthesized prior to the labelling period and became complexed to T-Ag sometime after synthesis. To investigate this possibility we performed Western analyses of T-Ag and p53 immunoprecipitates. As shown in Figure 2 , approximately equal amounts of T-Ag and p53 were present in complexes derived from most wt T-Ag-transformants when T-Ag was immunoprecipitated. This result was similar to that observed from analysis of metabolically labelled proteins ( Figure  1a ). The results from Western analysis of the tsA58 TAg transformants presented a dierent picture. T-Ag immunoprecipitates revealed that there was nearly an equal amount of p53 coprecipitated (Figure 3b and c). This was in contrast to the results from analysis of metabolically labelled proteins. Likewise, at steady state conditions a similar observation was made with pSRMT-NsiI-transformants, and p407/E-SV40 and p403/SV40 transformants ( Figure 3a , lanes 2 and 5 and d, lanes 1, 4 and 6). In these transformants, relatively large amounts of p53 coprecipitated with TAg. This indicates that the variant T-Ags form a complex with newly synthesized labelled p53 slowly or ineciently, but after sucient time complex formation is nearly complete.
The results also indicate that in tsA58 transformants incubated at 408C, the formation of complexes is especially slowed. This is suggested by the observation that immunoprecipitation of metabolically labelled TAg shows no coprecipitated p53 ( Figure 1c , lanes 2, 4, 6 and 8) while under steady state conditions, we observed signi®cant amounts of coprecipitated p53 ( Figure 3c , lanes 2, 4, 6 and 8). In these experiments the extracts were made from cells incubated for two or three days at 408C. We also found that in some tsA58-transformed cell clones the T-Ag/p53 complexes remained stable after incubation at 408C for 5 or 6 days. However, there was signi®cant variability in tsA58 immortalized human cells propagated at 408C. In some immortal cell clones, cells remained viable for longer periods and in some cell clones, complexes remained for more than 6 days. All tsA58 immortalized cell lines eventually died at 408C (not shown). With most cell clones incubated at 408C for periods longer than 6 days, the p53 levels were greatly reduced and many necrotic cells were observed. We have not yet determined if the low p53 levels were directly related to severe growth arrest or were a result of extensive cell necrosis.
The most surprising ®nding from the Western blots was that when p53 was immunoprecipitated from most wt and variant T-Ag transformants, most of the p53 was unbound to T-Ag ( Figure 3c , the amount of unbound p53 was slightly lower in cells grown for 2 days at 408 (not shown). These ®ndings indicate that at steady state conditions these transformants contain large amounts of unbound p53 but that most of the T-Ag is bound to Figure 1 , and then subjected to Western blotting. Equal amounts of proteins were boiled and then subjected to electrophoresis in 10% polyacrylamide gels. The proteins were transferred to Hybond membranes and reacted with a cocktail of monoclonal antibodies to T-Ag and p53 as described in Materials and methods. The blot was then reacted with HRP conjugated protein A and ®nally with an ECL reagent. Note that in most p53 immunoprecipitates, relatively little T-Ag is coprecipitated, except for clone 7 (lane 8). In the clone 3 transformant, the p53 band is much more intense than the T-Ag band, suggesting that each T-Ag molecule is bound by several p53 molecules. This anomaly was observed in repeated T-Ag immunoprecipitations of this transformant but was not in others. The transformants analysed in lanes 1 ± 4 are from HFB cells. All others are from HFF-495 cells. The T-Ag in lanes 1 and 2 is anomalously fast migrating. Lanes 11 and 12 were run on a dierent gel and the photo was spliced to lanes 1 ± 10. Because the conditions of the two gels were slightly dierent, the T-Ag bands appear to migrate faster, but in fact the mobilities are not dierent The results from comparative analyses of metabolically labelled proteins and Western blotting have indicated that in cells transformed by the variant TAgs, T-Ag/p53 complexes form slowly. Complexes may form slowly if one or both proteins must mature in order to form a complex and maturation is relatively slow (Kierstead and Tevethia, 1993) . While it is likely that the variant T-Ags have a relatively slower maturation rate, it is also possible that p53 has a slow rate of maturation. This is supported by the relative intensities of p53 bands in T-Ag immunoprecipitates compared to T-Ag bands in p53 immunoprecipitates from tsA58 transformants propagated at 378C (Figure 1b) . It is indicated that immunoprecipitation of metabolically labelled p53 appears to coprecipitate relatively more T-Ag while immunoprecipitation of metabolically labelled T-Ag appears to coprecipitate relatively less p53. More T-Ag is shown to be coprecipitated because much of the immunoprecipitated p53 is not 35 S-labelled but previously synthesized mature p53 which has bound some of the newly synthesized 35 S-labelled T-Ag. Similarly, Western immunoblots show that at steady state conditions most of the immunoprecipitated T-Ag is bound by p53 and that most of this p53 must have been previously synthesized protein (Figure 3b ). In contrast, even at steady state conditions immunoprecipitation of p53 shows very little T-Ag coprecipitated. This occurs because there is so much more p53 than T-Ag.
Also, a single p53 immunoprecipitation recovers less than ®fty percent of the p53 (shown below) leaving much of the bound T-Ag in the supernatant. Finally, as presented below, p53 monoclonal antibodies appear to react more eciently with p53 unbound to T-Ag.
Western analysis of sequential immunoprecipitates
If human cells transformed by variant T-Ags contain large amounts of p53 unbound to T-Ag then unbound p53 should also be detected by Western analysis of sequential immunoprecipitations. Wt and tsA58 SV40-transformed HFF495 cells were extracted to isolate proteins, and two types of sequential immunoprecipitation were begun with either T-Ag or p53 monoclonal antibodies. In the ®rst, we focused on p53. We immunoprecipitated p53 with DO-1 monoclonal antibody. The supernatant was saved, separated into three fractions and then one fraction was immunoprecipitated for T-Ag, and the other two immunoprecipitated for p53 using dierent p53 antibodies (DO-1 and PAb122). Then, each immunoprecipitate was subjected to Western analysis for the detection of the relative amounts of T-Ag and p53. In the second type of analysis we focused on T-Ag. We ®rst immunoprecipitated T-Ag and then separated the supernatant into fractions. One fraction was again immunoprecipitated for T-Ag and the others for p53. The results from these experiments are shown in Figure 4 with tsA58 transformants propagated at 378C but similar observations were made with wt T-Ag transformants.
When we focused our analysis on p53, the ®rst p53 immunoprecipitation reveals abundant p53 but, as expected, much less T-Ag is coprecipitated ( Figure  4a , lane 1). When the supernatant is immunoprecipitated for T-Ag, T-Ag is found to be abundant and is bound to nearly an equal amount of p53 (Figure 4a , lane 4). Immunoprecipitation of this second supernatant, using dierent p53 monoclonal antibodies, reveals the presence of still some p53, which is mostly unbound by T-Ag (Figure 4a, lanes 2 and 3) . These results indicate again that p53 is present in transformants in excess of T-Ag but most of the T-Ag is bound by p53. In addition, the ®rst p53 immunoprecipitation does not recover all of the p53, leaving much of it in the supernatant. p53 could still be recovered after a p53 immunoprecipitation, followed by a T-Ag immunoprecipitation and then a second p53 immunoprecipitation (Figure 4a, lane 5) . This again indicates large amounts of p53 are present.
When sequential immunoprecipitation begins with a T-Ag immunoprecipitation, the results lead to similar conclusions. The ®rst immunoprecipitation reveals abundant T-Ag and this T-Ag coprecipitated approximately an equal amount of p53 (Figure 4b, lane 1) . The ®rst supernatant contained very little T-Ag ( Figure  4b , lane 2) and this observation indicated that the ®rst T-Ag immunoprecipitation recovers nearly all of the TAg. After the second sequential T-Ag immunoprecipitation, the supernatant is shown to contain abundant p53, nearly all of which is unbound by T-Ag ( Figure  4b, lane 3) . Since a relatively large amount of p53 remained, it indicates that p53 is in excess of T-Ag.
Although p53 appeared to be in excess of T-Ag, the intensity of a p53 band from a p53 immunoprecipitation was usually not much greater than the intensity of a T-Ag band from a T-Ag immunoprecipitation (Figures 2 and 3 ). Also, a T-Ag immunoprecipitation recovers nearly all of the T-Ag (Figure 4b , lane 2) while a p53 immunoprecipitation recovers only a fraction of the p53 (Figure 4a lanes 2 and 3) . These observations suggest that p53 antibodies react with p53 less eciently than T-Ag antibodies react with T-Ag. However, since there is such a large amount of p53 present, the p53 antibodies may merely be in insucient quantity to recover all the p53. We examined this latter possibility by using more concentrated DO-1 p53 antibody solutions but no more p53 was detected (not shown). This suggested In addition to con®rming the presence of large amounts of unbound p53, the results demonstrate that the ®ndings gathered from analysis of metabolically labelled proteins can be misleading. Indeed, under steady state conditions T-Ag is largely bound by p53 in both wt and variant T-Ag transformed cells but all transformants contain large amounts of p53 which is unbound to T-Ag. These ®ndings were not apparent from the analysis of metabolically labelled proteins.
We note also that p53 monoclonal antibodies DO-1 and PAb122 appear to react better with p53 unbound to T-Ag rather than p53 bound to T-Ag. This is suggested by the following observations: (1) There was an extreme paucity of T-Ag which coprecipitated with p53 in some transformants under steady state conditions. (2) However, a T-Ag immunoprecipitation often coprecipitated at least an equal amount of p53. (3) A T-Ag immunoprecipitation followed by a p53 immunoprecipitation appears to recover most of the p53. We also performed three sequential p53 immunoprecipitations followed by a T-Ag immunoprecipitation. The second p53 immunoprecipitation recovered about 1/3 to 1/2 of the p53 recovered in the ®rst and the third p53 immunoprecipitation recovered little p53. However, in the ®nal immunoprecipitation for T-Ag, as much p53 was recovered as that in the ®rst p53 immunoprecipitation (not shown). Therefore, nearly all of the p53 which was complexed to T-Ag was observable only in a T-Ag immunoprecipitation. It is possible that two conformational types of p53 exist, one bound to T-Ag and the other free, and that p53 antibodies may react better with unbound p53. Alternatively, T-Ag binding to p53 may partially block access of p53 to monoclonal antibodies DO-1 and PAb122.
Simultaneous immunoprecipitation of T-Ag and p53, and Western analysis from direct lysates
In order to further con®rm the presence of large amounts of unbound p53, extracts from cells transformed by wt or tsA58 T-Ag which had been propagated at 378C were immunoprecipitated for both proteins with a cocktail of p53 and T-Ag antibodies. The proteins were then identi®ed on a Western blot. The results from two separate experiments show that in clone 2 HFF495 cells transformed by wt T-Ag, p53 is in great excess of T-Ag, perhaps ®ve to tenfold ( Figure  5a, lanes 1 and 2) . The HFF495 wt T-Ag clone 2 transformant was unlike most other wt T-Ag transformants as the others usually contained only a two to fourfold excess of p53 (Figure 5b ). In the HFF495 tsA58 clone 2 transformant, p53 was present in approximately a two to fourfold excess of T-Ag (Figure 5a, lane 3) . Using the cocktail of T-Ag and p53 antibodies, we then performed a sequential simultaneous T-Ag/p53 immunoprecipitation with extracts from the clone 2 tsA58 transformant. We compared these results with those from an immunoprecipitation of p53 and one of T-Ag. The second simultaneous immunoprecipitation of T-Ag and p53 recovered very little T-Ag but a signi®cant amount of p53, indicating still again that p53 was present in great excess of T-Ag immunoprecipitated with only anti-p53, no detectable T-Ag was coprecipitated (Figure 5a , lane 5). Consequently, the results of simultaneous immunoprecipitation experiments agree with those of sequential immunoprecipitation shown in Figure 4 . However, the p53 monoclonal antibodies do not appear to react with p53 as eciently as T-Ag monoclonal antibodies react with T-Ag. Therefore, more p53 may be present than indicated by the intensity of the p53 band and the ratio of p53 over T-Ag could be higher. In the second procedure, protein extracts were electrophoresed and transferred directly to nitrocellulose membranes without an intervening immunoprecipitation, and then probed directly for T-Ag and p53. In Figure 5b it is shown that again p53 is in excess of TAg, especially in HFF495 wt T-Ag clone 2 cells.
Discussion
Elucidation of the role of p53 in cell cycle control must reconcile apparently con¯icting observations. p53 was observed to inhibit cell cycle progression and then to be a competence factor for cell cycle progression (reviewed by Donehower and Bradley, 1993; Ullrich et al., 1992) . Similarly, analysis of the role of p53 in T-Ag transformation must assimilate new, not always con®rmatory observations. While cell transformation and immortalization by SV40 correlates with the ability of T-Ag to bind p53 (Zhu et al., 1991; Fukasawa et al., 1991; Kierstead and Tevethia, 1993; Lin and Simmons, 1991b) , several laboratories have shown that SV40 T-Ag transformed rodent cells contain p53, some of which is unbound to T-Ag (Deppert and Haug, 1986; Deppert et al., 1987; Kierstead and Tevethia, 1993; Michael-Michalovitz et al., 1991) . These ®ndings were usually made by immunoprecipitation analysis of metabolically pulselabelled proteins. Zhu et al., (1991) found that T-Ag mutants unable to bind pRb immortalized mouse embryo ®broblasts but mutants unable to bind p53 did not immortalize these cells. Lin and Simmons (1991b) studied transformation by SV40 T-Ag mutants in codon 402 of the p53 binding domain. While these mutant T-Ags could transform mouse cells and bind mouse p53 they transformed human cells poorly and bound human p53 poorly. After immunoprecipitation analysis of T-Ag/p53 complexes from metabolically labelled cells, they found that transformation correlated best with the relative percentage of T-Ag in TAg/p53 complexes rather than the relative percentage of p53 in the complexes.
Deppert's laboratory has shown that transformed rodent cells contained unbound p53. Deppert and Haug (1986) , using analysis of metabolically labelled proteins, showed that in transformed mouse and rat cells, metabolically stable p53 was present unbound to T-Ag. The stability of free p53 appeared not to depend on T-Ag binding. The relative amounts of T-Ag and p53 in transformants were not determined although the immunoprecipitates appeared to show p53 in small amounts. Deppert et al. (1987) found that metabolic stabilization of p53 occurred not only as a consequence of T-Ag binding but was related to expression of transformation. It was also shown that after introduction of wtSV40 large T-Ag into untransformed cells, progressive transformation occurred only in those cells which contained a p53 which could be stabilized and that transformation and stabilization of p53 correlated with the presence of both SV40 large T and small t antigens (Zerrahn and Deppert, 1993; Tiemann and Deppert, 1994a,b) .
Most of the early studies of T-Ag/p53 complexes in transformed cells were done using metabolically pulsed labelled proteins. Kierstead and Tevethia (1993) have shown that immunoprecipitation analysis of T-Ag/p53 complexes from metabolically labelled cells can sometimes be misleading because the labelled p53 or T-Ag in the complexes may represent only a fraction of these proteins present in complexes at steady-state levels. In addition, we suggest that the amount of uncomplexed proteins may also be greatly underrepresented when one relies solely on analysis of metabolically labelled proteins. It was shown by Kirstead and Tevethia (1993) that in cells transformed with some mutant T-Ags, the representation of either protein in the complexes was much greater at steady-state levels. It was suggested that this occurs when mutant T-Ag matures slowly and a short pulse-label (metabolic label) depicts labelled proteins largely before the complexes have been able to form. Therefore the results reported here were done using both immunoprecipitation analysis of T-Ag and p53 from metabolically labelled cells and analysis of proteins on Western blots.
Using Western analysis of T-Ag immunoprecipitates, we have shown here that human cells transformed by wt and variant SV40 T-Ags contain nearly equal amounts of T-Ag and p53 in T-Ag/p53 complexes. Most of the T-Ag is found complexed to p53. In contrast, Western analysis of p53 immunoprecipitates from human cells transformed by wt TAg, SV40 tsA58 T-Ag and other variant T-Ags, showed that most of the p53 was unbound to T-Ag. Also p53 was present in very large amounts, perhaps 200 times greater than in untransformed cells and usually two to four times greater than the amount of T-Ag. In one cell line, p53 was in tenfold excess of TAg. This was demonstrated by Western blotting of p53 immunoprecipitates, simultaneous immunoprecipitation of both T-Ag and p53 with antibodies to both proteins and by sequential immunoprecipitation of p53 or T-Ag. In tsA58-transformants, p53 is largely unbound to T-Ag when the cells are incubated at 338C, 378C or the non-permissive temperature of 408C. Nevertheless, p53 is again present in large amounts. Consequently, unbound p53 in transformed human cells must also be metabolically stable, as it is in some T-Ag transformed rodent cells (Deppert and Haug, 1986) . Our observations that p53 is present in perhaps 200-fold greater amounts in T-Ag transformants than in untransformed cells is consistent with the ®ndings of Benchimol et al. (1982) who showed that SV80 cells contained 100 times more p53 than in untransformed cells. While SV80 cells have a large amount of p53, immunoprecipitation analysis suggested no more p53 was present than T-Ag (Lane and Crawford, 1980; Crawford, 1983) .
When we compared complex formation analysed by metabolic labelling versus Western blotting, we found that in human cells transformed by variant T-Ags, TAg/p53 complexes formed more slowly than in cells transformed by wt T-Ag. This resulted not only from a slow maturation rate of T-Ag but also perhaps a slow maturation rate of p53. Newly synthesized variant TAg (e.g. tsA58 T-Ag) may bind predominantly mature p53 while wt T-Ag may bind p53 which is relatively immature. Alternatively, T-Ag may aect the maturation of p53 and some mutants may be de®cient in promoting p53 maturation (Kierstead and Tevethia, 1993) . Nevertheless, even though p53 may have to mature in order to bind T-Ag, it is present in great excess of T-Ag.
The observation that large amounts of unbound p53 persist in tsA58-transformed cells incubated at 408C was at ®rst unexpected because earlier analysis of metabolically labelled proteins showed that p53 binding by T-Ag was greatly reduced in these cells incubated at 408C (Figure 1) . The observation made from Western analysis suggests that the maturation rate of one or both proteins is especially slow when tsA58-transformants are incubated at 408C but that the complexes may form later.
Recently, we have established several tsA58 immortalized cell lines and have noted that although all ultimately fail to grow at 408C, there is signi®cant variability in how long the cells remain viable and how long a 408C incubation is required to eliminate complex formation. If p53 stability depends both on T-Ag and expression of the transformation phenotype, then p53 levels should be greatly reduced in tsA58-transformants incubated at 408C because these cells lose the transformed growth phenotype at 408C. While we have seen only a small reduction in p53 in most tsA58 transformants, it is possible that the cells must be incubated at 408C for prolonged periods (greater than 5 or 6 days) in order for p53 levels to return to that of untransformed cells. Because the cells begin to die after 5 or 6 days at 408C, it is dicult to perform this experiment on viable cells.
While p53 is in great excess of T-Ag, unbound p53 cannot control cell growth. Similar conclusions were made by Fukasawa et al. (1991) who showed that introduction of wt p53 did not cause transformation reversion of T-Ag transformed and established mouse cells. Although T-Ag transformed rodent and human cells reportedly contain wt p53 as indicated by PCR analysis and reactivity with monoclonal antibodies (Zakut-Houri et al., 1985; Lin and Simmons, 1990; Fukasawa et al., 1991; Moore et al., 1992) , it is possible that some human transformants contain mutant p53 which anomalously does not react with mutant speci®c' monoclonal antibody. It is also possible that the p53 in transformants has been modi®ed and acts like mutant p53 (Tiemann and Deppert, 1994a, b; Prives et al., 1991; Ullrich et al., 1992; and Meek, 1994) . It has been shown that T-Ag inhibits the p53 mediated transcriptional activation by binding to p53 (Farmer et al., 1992) . While it appears unlikely that this can be the only process which activates human cell growth since much of the p53 is free of T-Ag, it is possible that free p53 is inactivated by another mechanism. One possible mechanism is that p53 dissociates from T-Ag complexes but remains stable because of its previous association with T-Ag. Although this was argued against by Deppert et al. (1987) , it is conceivable that in the presence of even submolar amounts of T-Ag, the function of p53 is altered without the formation of a complex. Since in all cases nearly all of the T-Ag was bound by p53, it is possible that the T-Ag/p53 complex has transforming activity (Lin and Simmons, 1991b) , or the complex and free' p53 act in concert to induce transformation (Tiemann et al., 1995) .
Materials and methods
Cells and viruses
Human fetal spongioblasts (HFB-246) and human fetal ®broblasts (HFF495) were grown from trypsinization of therapeutically aborted fetal tissue as described (O'Neill et al., 1988) . CV-1 and BSC-1 are continuous lines of green monkey cells used for propagation of wtSV40, tsA58 SV40 and other SV40 variants. Several human transformants previously described (O'Neill et al., 1995) were used here. These include those transformed by E-SV40 encoded T-Ag derived from the variant EL-SV40 (O'Neill et al., 1982; and chimeric T-Ags [SV40/BKV-1 and SV40/JCV, also denoted as pSRSMT-NsiI]. SV40/BKV-I contains the C-terminal 38 amino acids from the BKV variant RFV TAg (O'Neill et al., 1992) . pSRSMT-NsiI contains the Cterminal 277 amino acids from JCV T-Ag (Haggerty et al., 1989) . Its p53 binding domain is also chimeric (Haggerty et al., 1989) . WtSV40 (strain 776), EL-SV40, tsA58 SV40 and pSRSMT-NsiI and other variant T-Ag constructs have been described (Haggerty et al., 1989; O'Neill et al., 1988 O'Neill et al., , 1990 O'Neill et al., , 1992 . The viruses were propagated in CV-1 or BSC-1 cells.
T-Ag gene molecular clones
WtSV40 DNA and tsA58 SV40 DNA were cloned into pUC19 and then subcloned into pSV 2 neo (Southern and Berg, 1982) . Before cloning, wtSV40 DNA was digested with EcoRV and the blunt ends were attached to EcoRI linkers. After digestion with EcoRI and self-ligation a 1200 bp fragment was deleted from the late region. The viral DNA was then cloned at the EcoRI site. TsA58 SV40 DNA does not have an EcoRV site. Therefore, it was digested with ApaI, blunt-ended and EcoRI linkers attached. Digestion with EcoRI and self-ligation released a 500 bp fragment inactivating the Vp1 gene and rendering the viral DNA non-infectious. tsA58 SV40 DNA was then cloned at the EcoRI site. (We have found that wtSV40 DNA cloned into plasmids at the BamHI site was often infectious when introduced into simian cells because of recombination within the recombinant vector followed by release of the wt viral genome. The deletions were introduced to mitigate the production of infectious viruses). E-SV40 DNA derived from the virus variant EL-SV40 had been previously cloned into pUC19 (O'Neill et al., 1993) .
p403/E-SV40 and p407/E-SV40 were pUC19 molecular clones of SV40 T-Ag genes recovered from human cells immortalized by chimeric SV40/BKV-1 T-Ag. The immortal cells (O'Neill et al., 1995) were found to contain episomal viral DNA in Hirt supernatants from which the viral DNA could be re-isolated. This viral DNA was re-isolated from two cell clones and then molecularly cloned into pUC19. Three distinct clones were recovered during this cloning and two of these were found to transform human cells.
Generation of new transformants
Some of the transformants investigated here were generated previously, including those produced by infection with tsA58 SV40 or transfection with chimeric T-Ags (O'Neill et al., 1995) . New transformants were produced by transfection of wtSV40 T-Ag genes, the tsA58 T-Ag recombinant cloned DNA, pSRSMT-NsiI, and p403/E-SV40 and p407/E-SV40 cloned DNAs (Chen and Okayama, 1987; Haggerty et al., 1989; O'Neill et al., 1992 O'Neill et al., , 1995 . Transformants were identi®ed as dense foci and the frequency of transformation was scored in the dense focus assay as described (O'Neill et al., 1988 (O'Neill et al., , 1995 . Several dense foci were assayed for T-Ag and all were positive. Transfected cells were propagated at 378C. Transformants were isolated as described and then propagated at 338C, 378C or 408C (O'Neill et al., 1988 (O'Neill et al., , 1995 . All tsA58-induced transformants grew poorly at 408C and after 5 or 6 days growth was usually completely arrested and the cells eventually died. T-Ag and p53 were analysed from these cells usually after 2 or 3 days and sometimes after 5 or 6 days incubation at 408C. After longer periods, there was the risk of large numbers of necrotic cells. In contrast, transformants generated with wt T-Ag, pSRSMT-NsiI, p403/E-SV40 and p407/E-SV40 propagated continuously at 338C, 378C and 408C.
T-Ag and p53 analysis
T-Ag and p53 were analysed by immunoprecipitation and Western blot methodologies (Ausubel et al., 1987) . For immunoprecipitation, growing cells were incubated with 35 S-translabel (methionine) for 4 h. Lysates were precleared by absorption with staphylococcus aureus Protein A overnight at 48C, and then microcentrifuged for 30 min. Samples were quantitated by counting radioactivity in LCS. Either 6 ml of monoclonal antibody-ascites¯uid (DO-1) or 200 ml of monoclonal antibody-tissue culture supernatant¯uid (PAb122, PAb416 or PAb101/108) and 30 ml of 50% protein A-Sepharose beads in lysis buer were added to each 800 ml of extract. The mixtures were rotated overnight at 48C. Immune complexes were washed four times in wash buer (50 mM Tris pH 7.4), 500 mM NaCl, 5 mM EDTA, 5% sucrose, 1% Niodet P-40, 1 mM Phenylmethlsulfonyl Fluoride (PMSF), once in 0.5 M LiCl, once in wash buer and once in double distilled H 2 O. The proteins were dissociated from protein A-Sepharose beads by boiling for 10 min at 1008C. Immunoprecipitates were then subjected to electrophoresis in SDS-10% polyacrylamide gels (PAGE). T-Ag was immunoprecipitated from lysates using PAb101+PAb108 or PAb416+PAb108. p53 was immunoprecipitated using PAb122, PAb240 or DO-1 (Vojtesek et al., 1992) . DO-1 was purchased from commercial suppliers. PAb122 producing hybridoma cells was a kind gift of Dr Elizabeth Gurney. PAb122 is directed against mouse p53 and DO-1 against human p53 (Gurney et al., 1980; Vojtesek et al., 1992) . The PAb240 producing hybridoma cells were a kind gift of Dr David Lane. PAb240 immunoprecipitates only mutant p53 but not wt p53 . It did not immunoprecipitate p53 from SV40 T-Ag transformed human cells but did immunoprecipitate p53 from the human breast cancer cell line BT-20 (not shown). BT-20 cells had earlier been shown to contain mutant p53 (Bartek et al., 1990) . We could ®nd no dierence in the ability of the dierent T-Ag monoclonal antibodỳ cocktails' to recover T-Ag. Immunoprecipitation of TAg recovered at least 90% of the T-Ag in the extract. We could recover T-Ag equally well from both transformed cells (where T-Ag was bound to p53) and from abortively transfected cells (where most of the T-Ag was unbound). This indicated that T-Ag monoclonal antibodies did not react more eciently with bound or unbound T-Ag. In contrast, immunoprecipitation of p53 with DO-1 or PAb122 recovered, we estimate, only 30 ± 40% of the p53 in the extract.
Western analysis was done on T-Ag immunoprecipitates, p53 immunoprecipitates or directly from cell lysates. For direct lysates rapidly growing cell monolayers were washed twice with PBS (pH 7.4) and once with washing medium (125 mM NaCl, 25 mM Tris [pH 8.0]). Cells were lysed on the plate with 100 ml of lysis buer (50 mM Tris [pH 8.01]), 120 mM NaCl 1 mM DTT, 0.5% NP40, 1 mM PMSF) for 5 min at 4 8 C. The cells in the lysis buer were scraped into a microfuge tube and cell debris were pelleted by centrifugation at 14000 r.p.m. for 5 min at 48C. Protein concentrations were determined by Bradford assay (Bio-Rad Kit). An equal volume of 26SDS sample buer (200 mM Tris [pH 6.8]), 200 mM b-mercaptoethanol, 4% SDS, 20% glycerol, 0.04% bromphenol blue) was added, mixed and stored at 48C. The proteins were run under denaturing conditions on polyacrylamide gels, transferred to nitrocellulose membranes and probed with primary antibodies: PAb101+PAb108 or PAb416+PAb108 for T-Ag and DO-1 or PAb122 for p53. We found that with Western blots, PAb416 gave a slightly stronger reaction for T-Ag than a combination of PAb101+PAb108. DO-1 and PAb122 reacted with p53 equally on Western blots and appeared to recover nearly the same amount of p53 in immunoprecipitates. After reaction with monoclonal antibodies against T-Ag and p53 proteins, the blots were reacted with horseradish peroxidase (HRP) tagged protein A followed by an ECL reaction (Yolken and Leister, 1981; Gee and Langone, (1981) . This was crucial in avoiding the complication of IgG heavy chain bands superimposed on p53 bands which can result in a falsepositive p53 band. The protein A reaction replaced the reaction which used HRP conjugated anti-mouse IgG, or F(ab') 2 fragments, both of which we found reacted with denatured heavy chains immobilized on membranes. The detection method utilizing HRP-protein A reacted only with undenatured immunoglobulins from the probing antibodies and not with those from the immunoprecipitation reaction. The immunoprecipitates were denatured by boiling for ®ve minutes just before electrophoresis. For Western analysis made directly from lysates, we avoided the use of HRPprotein A because in this system it resulted in some background. Instead, we identi®ed T-Ag and p53 with HRP anti-mouse IgG, F(ab') 2 fragments followed by the ECL reaction.
Testing the Fidelity of Antibody Identi®cation of T-Ag and p53
In order to test the ®delity of the monoclonal antibody identi®cation of T-Ag and p53, we performed a control experiment with extracts of untransformed, T-Ag negative cells. The extract was ®rst immunoprecipitated for T-Ag and the supernatant from this reaction then immunoprecipitated for p53. Both immunoprecipitates were then probed for T-Ag and p53 on Western blots. We used the HRP-protein A reaction to identify T-Ag and p53. As expected, no T-Ag and no p53 were detected (not shown). This indicated that in transformed cells, the persistence of p53 bands through sequential immunoprecipitations was not a technical artifact. An artifact could result from the accumulation of heavy chain antibody proteins which may have spuriously reacted with the HRP-protein A detecting system used to identify the two proteins on Western blots. As described above, our HRPprotein A detection system will not react with the immunoprecipitating antibodies and this control experiment demonstrates this. In contrast, when we used HRPanti-mouse IgG or F(ab') 2 to identify T-Ag and p53 a band appeared near the position for p53.
